Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

7,500 lung cancer patients join study to speed up biomarker testing

NCT ID NCT05885698

Knowledge-focused Sponsor: US Oncology Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 7,500 people with newly diagnosed non-small cell lung cancer to see how quickly they get biomarker tests and whether those tests help doctors choose the right treatment. Researchers want to find out what slows down testing, such as tissue problems or insurance issues. The goal is to improve testing in community cancer centers so more patients get personalized therapy sooner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 7,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2023

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment naive non-small cell lung cancer.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult subjects (18 years and older) with newly diagnosed early stage, locally advanced or metastatic non-small cell lung cancer * Must be eligible for systemic therapy based on the treating provider's assessment. If systemic therapy was recommended and documented by the treating provider but the patient declined, they can still be eligible for the study. Patients can be enrolled prior to start of treatment. * Subjects who developed locally advanced or metastatic disease after receiving adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of locally advanced or metastatic disease * Subjects must be enrolled within 30 days of initiation of systemic therapy * Signed informed consent Exclusion Criteria: * Stage IA at the time of enrollment * Subjects with small cell lung cancer * Subjects with Unknown primary tumor origin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, non-small-cell lung are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, non-small-cell lung

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Oncologists, LLC

    RECRUITING

    Chicago Ridge, Illinois, 60415, United States

  • Arizona Oncology Associates, PC - NAHOA

    NOT_YET_RECRUITING

    Prescott Valley, Arizona, 86314, United States

  • Cancer Care Centers of Brevard, Inc.

    RECRUITING

    Palm Bay, Florida, 32901, United States

  • Illinois Cancer Specialists

    ACTIVE_NOT_RECRUITING

    Niles, Illinois, 60714, United States

  • Maryland Oncology Hematology, P.A.

    ACTIVE_NOT_RECRUITING

    Silver Spring, Maryland, 20904, United States

  • Minnesota Oncology Hematology, P.A.

    ACTIVE_NOT_RECRUITING

    Minneapolis, Minnesota, 55404, United States

  • New York Oncology Hematology, P.C.

    RECRUITING

    Albany, New York, 12208, United States

  • Northwest Cancer Specialists, P.C.

    RECRUITING

    Vancouver, Washington, 98684, United States

  • Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

    RECRUITING

    Blacksburg, Virginia, 24060, United States

  • Oncology Hematology Care Clinical Trials, LLC

    RECRUITING

    Cincinnati, Ohio, 45242, United States

  • Rocky Mountain Cancer Center

    ACTIVE_NOT_RECRUITING

    Denver, Colorado, 80218, United States

  • Shenandoah Oncology, P.C.

    ACTIVE_NOT_RECRUITING

    Winchester, Virginia, 22601, United States

  • Southern Cancer Center, PC

    RECRUITING

    Daphne, Alabama, 36526, United States

  • Virginia Cancer Specialists, PC

    ACTIVE_NOT_RECRUITING

    Fairfax, Virginia, 22031, United States

  • Virginia Oncology Associates

    RECRUITING

    Newport News, Virginia, 23606, United States

  • Willamette Valley Cancer Institute and Research Center

    RECRUITING

    Eugene, Oregon, 97401, United States

  • Woodlands Medical Specialists, PA

    ACTIVE_NOT_RECRUITING

    Pensacola, Florida, 32503, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.